BRIEF published on 11/13/2024 at 07:35, 8 days 2 hours ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
BRIEF published on 11/13/2024 at 07:35, 8 days 2 hours ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 8 days 2 hours ago Informations privilégiées / Autres communiqués GenSight Biologics soumet le dossier de LUMEVOQ® à l'ANSM pour reprendre le programme d'accès compassionnel en France. Premieres injections prévues en décembre 2024 Thérapie Génique GenSight Biologics LUMEVOQ ANSM Neuropathie Optique
PRESS RELEASE published on 11/13/2024 at 07:30, 8 days 2 hours ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 19 days 15 hours ago GenSight Biologics obtient un financement de 2,8 millions d'euros Financement Thérapie Génique Mandats GenSight Biologics Maladies De La Rétine
BRIEF published on 11/01/2024 at 18:23, 19 days 15 hours ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 19 days 15 hours ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
PRESS RELEASE published on 11/01/2024 at 18:18, 19 days 15 hours ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 2,8 millions d’euros auprès d’investisseurs existants pour soutenir le développement de thérapies géniques innovantes Développement Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 10/24/2024 at 21:13, 27 days 12 hours ago GenSight Biologics dévoile sa situation de trésorerie et avance sur le LUMEVOQ® Financement Trésorerie LUMEVOQ® Accès Compassionnel ANSM
BRIEF published on 10/24/2024 at 21:13, 27 days 12 hours ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
Published on 11/21/2024 at 09:00, 47 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 12 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 22 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 47 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 47 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 08:59, 47 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 47 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 32 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 38 minutes ago KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 40 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 27 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting